Squamous cell carcinoma of gallbladder and extrahepatic biliary tract

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:424996C23C24.0C24.1
Who is this for?
Show terms as
1FDA treatments6Specialists8Treatment centers2Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Squamous cell carcinoma of the gallbladder and extrahepatic biliary tract is a rare and aggressive type of cancer that starts in the flat, scale-like cells lining the gallbladder or the bile ducts outside the liver. The bile ducts are tubes that carry bile — a digestive fluid — from the liver and gallbladder to the small intestine. This cancer is sometimes called squamous cell carcinoma of the biliary tract or SCC of the gallbladder. It is different from the more common adenocarcinoma of the gallbladder, which starts in gland-forming cells. Squamous cell carcinoma makes up only a small fraction of all gallbladder and bile duct cancers. This cancer often grows silently in its early stages, which means many people are not diagnosed until the disease has already spread. When symptoms do appear, they can include yellowing of the skin and eyes (jaundice), belly pain, nausea, and unexplained weight loss. The gallbladder sits under the liver on the right side of the abdomen, and tumors there can block the flow of bile, causing a buildup that leads to jaundice and digestive problems. Treatment usually involves surgery to remove the tumor when possible, along with chemotherapy and sometimes radiation therapy. Unfortunately, because this cancer is often found late, the outlook can be challenging. Research into better treatments is ongoing, and care from a specialized cancer team can make a meaningful difference in quality of life and outcomes.

Also known as:

Key symptoms:

Yellowing of the skin and whites of the eyes (jaundice)Pain or discomfort in the upper right side of the abdomenNausea and vomitingUnexplained weight lossLoss of appetiteDark-colored urinePale or greasy stoolsItchy skinFeverFeeling very tired or weakA lump or swelling in the abdomen

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

Treatments

1 available

Tagrisso

osimertinib· AstraZeneca Pharmaceuticals LP
in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21

in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test

No actively recruiting trials found for Squamous cell carcinoma of gallbladder and extrahepatic biliary tract at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Squamous cell carcinoma of gallbladder and extrahepatic biliary tract community →

Specialists

6 foundView all specialists →
SP
Sandip P Patel
Birmingham, Alabama
Specialist

Rare Disease Specialist

PI on 1 active trial
SM
Scot C. Remick, MD
SCARBOROUGH, ME
Specialist
PI on 9 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

2 resources
Tagrisso(osimertinib)AstraZeneca Pharmaceuticals LP

OPDIVO

E.R. Squibb & Sons, L.L.C.

OPDIVO — Contact E.R. Squibb & Sons, L.L.C.

Unverified — confirm before calling
Patient Assistance
Manufacturer Program
Accepting applications

Travel Grants

No travel grants are currently matched to Squamous cell carcinoma of gallbladder and extrahepatic biliary tract.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Squamous cell carcinoma of gallbladder and extrahepatic biliary tractForum →

No community posts yet. Be the first to share your experience with Squamous cell carcinoma of gallbladder and extrahepatic biliary tract.

Start the conversation →

Latest news about Squamous cell carcinoma of gallbladder and extrahepatic biliary tract

No recent news articles for Squamous cell carcinoma of gallbladder and extrahepatic biliary tract.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What stage is my cancer, and has it spread beyond the gallbladder or bile ducts?,Is surgery an option for me, and what would that involve?,What chemotherapy or other treatments do you recommend, and what are the side effects?,Should my tumor be tested for specific mutations that might make me eligible for targeted therapy or a clinical trial?,Are there clinical trials I should consider?,What signs or symptoms should prompt me to call you or go to the emergency room?,What palliative or supportive care services are available to help manage my symptoms and quality of life?

Common questions about Squamous cell carcinoma of gallbladder and extrahepatic biliary tract

What is Squamous cell carcinoma of gallbladder and extrahepatic biliary tract?

Squamous cell carcinoma of the gallbladder and extrahepatic biliary tract is a rare and aggressive type of cancer that starts in the flat, scale-like cells lining the gallbladder or the bile ducts outside the liver. The bile ducts are tubes that carry bile — a digestive fluid — from the liver and gallbladder to the small intestine. This cancer is sometimes called squamous cell carcinoma of the biliary tract or SCC of the gallbladder. It is different from the more common adenocarcinoma of the gallbladder, which starts in gland-forming cells. Squamous cell carcinoma makes up only a small fractio

How is Squamous cell carcinoma of gallbladder and extrahepatic biliary tract inherited?

Squamous cell carcinoma of gallbladder and extrahepatic biliary tract follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Squamous cell carcinoma of gallbladder and extrahepatic biliary tract typically begin?

Typical onset of Squamous cell carcinoma of gallbladder and extrahepatic biliary tract is adult. Age of onset can vary across affected individuals.

Which specialists treat Squamous cell carcinoma of gallbladder and extrahepatic biliary tract?

6 specialists and care centers treating Squamous cell carcinoma of gallbladder and extrahepatic biliary tract are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Squamous cell carcinoma of gallbladder and extrahepatic biliary tract?

1 patient support program are currently tracked on UniteRare for Squamous cell carcinoma of gallbladder and extrahepatic biliary tract. See the treatments and support programs sections for copay assistance, eligibility, and contact details.